Table 5.
Bone marrow and circulating progenitor cells in coronary artery disease patients
| Ref. | n | Randomize | Time post PCI and/or MI | Cell dose | Injection route | Baseline LVEF | LVEF change | Duration | Other findings |
| Assmus et al[215] | 92 | Yes | 2348-2470 d | 22 ± 106 CPC 205 ± 110 × 106 BMC | IC | CPC 39% ± 10% BMC: 41% ± 11% | CPC -0.4% BMC 2.90% | 3 mo | Pts with previous MI; ↑ LVEF in BMC but not CPC |
| Bartunek et al[216] | 35 | Cohort | 10 d | 12.6 ± 2.2 × 106 | IC | 45% ± 2.5% | 7% | 4 mo | ↑ LV regional function, perfusion; restenosis ↑ |
| Chen et al[217] | 69 | Yes | 18.4 ± 0.5 d | 8-10 × 109 | IC | 49% ± 9% | 18% | 6 mo | ↑ LVEF by ventriculogram ↑ perfusion; ↓ ESV |
| Erbs et al[218] | 26 | Yes | 225 ± 87 d | 69 ± 14 × 106 | IC | 51.7% ± 3.7% | 7.20% | 3 mo | Pts with chronic CAD occlusion Rxed with CPC; ↓ EF by MRI; infarct size 16% |
| Ge et al[219] | 20 | Yes | 1 d | 39 ± 22 × 106 | IC | 53.8% ± 9.2% | 4.80% | 6 mo | ↑ Perfusion by SPECT |
| Hendrikx et al[220] | 20 | Yes | 217 ± 162 d | 60 ± 31 × 106 IM | IM | 42.9% ± 10.3% | 5% | 4 mo | CABG in Pts with previous CAD ↑ Regional but not global LV function; 6/9 with induced ventricular tachycardia |
| Janssens et al [221] | 67 | Yes | 1 d | 172 × 106 | IC | 48.5 ± 7.2 | 3.30% | 4 mo | ↓ Infarct size |
| Kang et al[222] | 96 | Yes | < 14 d AMI; > 14 d OMI | 1-2 × 109 | IC | 52.0 ± 9.9 | 5.10% AMI | 6 mo | G-CSF for 3 d; ↓ ESV and infarct size in AMI; = EF, ESV and infarct size in OMI |
| Katritsis et al[223] | 22 | Cohort | 224 ± 464 d | 2-4 × 106 | IC | 39.7% ± 9.3% | 1.60% | 4 mo | ↑ Regional but not global LV function |
| Lunde et al[224,225] | 100 | Yes | 6 ± 1.3 d | 68 × 106 (median) 54-130 × 106 | IC | 41.3 ± 11.0 | = | 6-12 mo | ↑ LVEF in treated and controls; = EDV and infarct size |
| Meyer et al[226] | 60 | Yes | 4.8 ± 1.3 | 24.6 ± 9.4 × 108 | IC | 50 ± 10 | 5.90% | 18 ± 6 mo | ↑ LVEF by MRI significant at 6 but not 18 mo |
| Mocini et al[227] | 36 | Cohort | AMI < 6 mo | 292 ± 232 × 106 IM | IM | 46% ± 6% | 5% | 3-12 mo | CABG in all; troponin increased |
| Perin et al[228] | 20 | Cohort | ICM | 25.5 ± 6.3 × 106 | IM Trans-Endo-cardial | 30% ± 6% | 5.10% | 12 mo | LVEF = Controls; ↑ LV perfusion ↑ Exercise |
| Ruan et al[229] | 20 | Yes | Approximately 1 d | NR | IC | 53.5% ± 5.8% | 5.80% | 6 mo | ↑ LV segmental contraction |
| Schächinger et al[230,231] | 204 | Yes | 3-8 d | 2.4 × 108 | IC | 48.3% ± 9.2% | 6%-7% | 4-12 mo | ↑ EF when Rx > 4 d post MI and when EF ↑ ≤ 48.9; LV perfusion |
| Strauer et al[232] | 20 | Cohort | 5-9 d | 2.8 ± 2.2 × 107 IM | IC | 57% ± 8% | 5% | 3 mo | ↑ Regional but not global LVEF; ↓ ESV and ↓ Infarct size |
| Li et al[234] | 70 | Yes | 7 ± 5 d | 7.3 ± 7.3 × 107 | IC | 50% ± 8.2% | 7% | 6 mo | G-CSF for 5 d; ↓ LV ESV, ↓ LV wall motion score |
NR: Not recorded or equals no change; CPC: Circulating progenitor cells; BMC: Bone marrow cells; ICM: Ischemic cardiomyopathy; IC: Intracoronary injection; IM: Intramyocardial injection; AMI: Acute myocardial infarction; OMI: Old myocardial infarction; G-CSF: Granulocyte colony stimulating factor; ESV: LV end-systolic volume; SPECT: Single photon emission computer tomography. Adapted from Henning[213].